REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. trimmed its position in REGENXBIO Inc. (NASDAQ:RGNX) by 4.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 214,353 shares of the biotechnology company’s stock after selling 11,064 shares during the quarter. Principal Financial Group Inc. owned approximately 0.44% of REGENXBIO worth $2,249,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of RGNX. ProShare Advisors LLC raised its stake in REGENXBIO by 8.3% in the first quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock valued at $240,000 after buying an additional 874 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of REGENXBIO by 33.3% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,485 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 3,870 shares in the last quarter. Vanguard Group Inc. raised its position in shares of REGENXBIO by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company’s stock worth $102,756,000 after acquiring an additional 436,043 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in REGENXBIO by 12.3% during the first quarter. CANADA LIFE ASSURANCE Co now owns 37,211 shares of the biotechnology company’s stock worth $783,000 after purchasing an additional 4,076 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in REGENXBIO by 8.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 18,177 shares of the biotechnology company’s stock valued at $383,000 after purchasing an additional 1,438 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the transaction, the director now directly owns 11,286 shares in the company, valued at $114,101.46. The trade was a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 13.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on RGNX shares. Barclays cut their price objective on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. HC Wainwright cut their price target on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday. Raymond James restated an “outperform” rating and issued a $18.00 price objective on shares of REGENXBIO in a research note on Thursday, October 10th. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Finally, Chardan Capital reissued a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a report on Wednesday. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $35.27.

REGENXBIO Trading Up 4.5 %

Shares of RGNX stock opened at $9.59 on Friday. The company has a market capitalization of $475.14 million, a P/E ratio of -1.91 and a beta of 1.23. The business’s 50 day moving average is $10.31 and its two-hundred day moving average is $12.12. REGENXBIO Inc. has a twelve month low of $8.53 and a twelve month high of $28.80.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.